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Why we prepare tablet in tablet of Magnesium glycine complex and Vitamin D3 
1. Normaly, single Vitamin D3 tablets are easily degrade in moisture content and 
temperature. So, overages add 100% then the half life should be 6 months or 
one year. But in the tablet in tablet formulation, prevent the degradation. Here 
overages added only 50%. Then the half life become two years. 
2. Single vitamin D3 tablets sometimes leads to side effect, it is prevented by 
combined with magnesium. 
3. Magnesium and vitamin D essential for bone synthesis otherwise intensify to 
Osteoporosis. Mg is also credited with stabilizing function in bone building. 
If there is no stabilizing function of magnesium during bone synthesis this also 
degrease in bone density. 
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1.INTRODUCTION
Solid medicaments may be administered orally as powders, pills, cachets,
capsules or tablets [1].These dosage forms contain a quantity of drug which is
given as a single unit and they are known collectively as solid unit dosage forms,
even in the case of sustained action preparations which, technically, contain the
equivalent of several normal doses of drug .The stringent formulation
requirements of modern medicaments, the many advantages of tablet and
capsule medication, coupled with expanding health services and the commitment
need for large‐scale economic manufacture, have led to a steady decline in the
prescribing of powders and pills [2] .Tablets and capsules, on the other hand,
currently account for well over two third of the total number and cost of medicines
produced all over the world. Tablet is defined as a compressed solid dosage form
containing medicaments with or without excipients [3]. According to the Indian
Pharmacopoeia Pharmaceutical tablets are solid, flat or biconvex dishes, unit
dosage form, prepared by compressing a drugs or a mixture of drugs, with or
without diluents. They vary in shape and differ greatly in size and weight,
depending on amount of medicinal substances and the intended mode of
administration. It is the most popular dosage form and 70% of the total medicines
are dispensed in the form of Tablet. All medicaments are available in the Tablet
form except where it is difficult to formulate or administer [4].
The advantages of the Tablet dosage form are: They are unit dosage form
and offer the greatest capabilities of all oral dosage form for the greatest dose
precision and the least content variability.
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 Cost is lowest of all oral dosage form.
 Lighter and compact.
 Easiest and cheapest to package and strip.
 Easy to swallowing with least tendency for hang‐up.
 Sustained release product is possible by enteric coating.
 Objectionable odour and bitter taste can be masked by coating
technique.
 Suitable for large scale production.
 Greatest chemical and microbial stability over all oral dosage form.
 Product identification is easy and rapid requiring no additional steps
when employing an embossed and/or monogrammed punch face [5].
Disadvantages of Tablet dosage form are:
 Difficult to swallow in case of children and unconscious patients.
 Some drugs resist compression into dense compacts, owing to
amorphous nature, low density character.
 Drugs with poor wetting, slow dissolution properties, optimum
absorption high in GIT may be difficult to formulate or manufacture as a
tablet that will still provide adequate or full drug bioavailability.
 Bitter testing drugs, drugs with an objectionable odor or drugs that are
sensitive to oxygen may require encapsulation or coating. In such
cases, capsule may offer the best and lowest cost [6].
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General properties of Tablet dosage forms: A tablet should have elegant
product identity while free of defects like chips, cracks, discoloration, and
contamination.
 Should have sufficient strength to withstand mechanical shock during
its production packaging, shipping and dispensing.
 Should have the chemical and physical stability to maintain its physical
attributes over time
 The tablet must be able to release the medicinal agents in a
predictable and reproducible manner.
 Must have a chemical stability over time so as not to follow alteration of
the medicinal agents [7].
Different types of Tablets
(A) Tablets ingested orally:
 Compressed tablet, e.g. Paracetamol tablet
 Multiple compressed tablet
 Repeat action tablet
 Delayed release tablet, e.g. Enteric coated Bisacodyl tablet
 Sugar coated tablet, e.g. Multivitamin tablet
 Film coated tablet, e.g. Metronidazole tablet
 Chewable tablet, e.g. Antacid tablet [8].
(B) Tablets used in oral cavity:
 Buccal tablet, e.g. Vitamin‐c tablet
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 Sublingual tablet, e.g. Vicks Menthol tablet
 Troches or lozenges
 Dental cone
(c) Tablets administered by other route:
 Implantation tablet
 Vaginal tablet, e.g. Clotrimazole tablet[9].
(D) Tablets used to prepare solution:
 Effervescent tablet, e.g. Dispirin tablet (Aspirin)
 Dispensing tablet, e.g. Enzyme tablet (Digiplex)
 Hypodermic tablet
 Tablet triturates e.g. Enzyme tablet (Digiplex)
Tablet Ingredients In addition to active ingredients, tablet contains a number
of inert materials known as additives or excipients.
Different excipients are:
1. Diluent
2. Binder and adhesive
3. Disintegrents
4. Lubricants and glidants
5. Colouring agents
6. Flavoring agents
7. Sweetening agents [10].
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Granulation technology on large scale by various techniques
Fig 1:1 Granulation Technology
VITAMIN D3
Vitamin D3(cholecalciferol) is derived from 7-dehyrocholesterol and involved in
bone health. Scientists have recognized that, depression, back pain, cancer, both
insulin resistance and pre-eclampsia during pregnancy, impaired immunity and
macular degeneration are directly linked to the Vitamin D3 deficiency
[11].Inadequate Vitamin D3 may cause secondary hyperparathyroidism that
increases the risk of osteoporosis and fractures and change the regulatory
mechanisms of parathyroid hormone (PTH) [12,13]. Other types of condition such
as high blood pressure, fibromyalgia, diabetes, multiple sclerosis, rheumatoid
arthritis has been linked to the low levels of Vitamin D3 [14,15]. Vitamin D3
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deficiency is responsible psychiatric and neurologic disorders and associated
with low mood [16].
Fig 1:2 Vitamin D metabolism
ORAL TABLETS: Standard compressed tablets e.g. Paracetamol tablet Multiple
compressed tablets I. Compression coated tablet- sugar coated tablet, Film coated
tablet, Gelatin coated tablet, Enteric coated tablet  II. Layered tablet  III. Inlay tablet
Targeted tablet[17,18,19].
Fig 1:3 vitamin D Deficiency
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Fig 1:4 Vitamin D Metabolism
I. Floating tablet  II. Colon targeting tablet
Different types of Tablets:
Tablets ingested orally: 1. Compressed tablet, e.g. Paracetamol tablet 2. Multiple
compressed tablet 3. Repeat action tablet 4. Delayed release tablet, e.g. Enteric
coated Bisacodyl tablet 5. Sugar coated tablet, e.g. Multivitamin tablet 6. Film coated
tablet, e.g. Metronidazole tablet 7. Chewable tablet, e.g. Antacid tablet[20,21,22].
Tablets used in oral cavity: 1. Buccal tablet, e.g. Vitamin‐c tablet 2. Sublingual tablet,
e.g. Vicks Menthol tablet 3. Troches or lozenges 4. Dental cone [23,24]. Tablets
administered by other route: 1. Implantation tablet 2. Vaginal tablet, e.g. Clotrimazole
tablet (D)[25,26]. Tablets used to prepare solution: Effervescent tablet, e.g. Dispirin
tablet (Aspirin) 2. Dispensing tablet, e.g. Enzyme tablet (Digiplex) 3. Hypodermic
tablet 4. Tablet triturates e.g. Enzyme tablet (Digiplex)[27,28].
Department of Pharmaceutics AKCP
IN
T
R
O
D
U
C
T
IO
N
8
Tablet-in-tablet technology: Tablets are indeed the most popular solid dosage form
for oral administration. One category of tablet formulations that has gained
remarkable importance in drug therapeutics owing to various benefits it offers is
controlled or modified release formulations[29,30,31] . Although less popular, tablet-
in-atablet technology (see Fig 1) gained increased interest in the recent years for
creating modified released products[32,33]. It involves the compaction of granular
materials around a preformed tablet core using specially designed tableting
equipment. Compression coating is a dry process [34,35,36]. This type of tablet
(compression coated tablet) has two parts, internal core and surrounding coat
[37,38]. The core is small porous tablet and prepared on one turret. After tablet core
manufacture it is transferred (centrally positioned) to another slightly larger die that is
partially filled with coating powder. More coating powder is filled on the top of the
core and compressed again resulting in tablet with in tablet. Mechanically, it is a
complex process, as the tablet may be tilted when transferred to the second die
cavity. Mostly, the coat is water soluble and disintegrates easily after swallowing, in
order to achieve immediate release product. This tablet readily lend itself in to a
repeat action tablet as the outer layer provides the initial dose while the inner core
release the drug later on. But, when the core quickly releases the drug, entirely
different blood level is achieved with the risk of over dose toxicity. To avoid
immediate release of both the layers, the core tablet is coated with enteric polymer
so that it will not release the drug in stomach while, the first dose is added in outer
sugar coating. Even so, coating operation requires interpretation while manufacturing
and dawdling the manufacturing process. Sometimes, inner core may be of liquid
formulation to provide immediate release of core after the coat gets dissolved
[39,40]. Tablet coating is the key step involved in the manufacturing of tablets having
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controlled release, delayed release profiles. The tablet coating have number of
advantages like masking odor, taste, color of the drug, providing physical and
chemical protection to drug, Protecting drug from the gastric environment. Tablets
are usually coated in horizontal rotating pan with coating solution is either directly
poured or sprayed on to them. The amount of coating on the surface of a tablet is
critical to the effectiveness of the oral dosage form. Recent trends in tablet coating
focuses on overcoming disadvantage of solvent based coating. This review concerns
with the coating process, equipment’s involved, coated tablets evaluation and
specialized coating techniques. Tablets are usually coated in horizontal rotating pans
with the coating sprayed onto the free surface of the tablet bed. Tablets must have a
coating mass that lies within a prescribed range with very little inter-and intra-tablet
coating variability. Using the Discrete Element Method (DEM) tablet coating can be
simulated on the computer [41,42,43].
Fig 1:5 Formulation Tablet in Tablet
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Fig 1:6 Compressed Core Tablet System
Simulation data provide the position, velocity and orientation of each tablet within the
coater allowing accurate measurements of the time and orientation that each tablet
spends exposed to the coating spray. The blend was compressed on a single punch
machine, tablets were subjected to various tests (weight variation, diameter and
thickness, hardness, disintegration and assay of the drug) and the results were also
in compliance with the official specifications [44, 45,46,47].
Fig1:7 Tablets Various Compression
Department of Pharmaceutics AKCP
IN
T
R
O
D
U
C
T
IO
N
11
Fig 1:8 Core Tablet Designed
Coating techniques: - Generally three methods are used for tablet coating A) Sugar
coating. B) Film coating. C) Enteric coating.
A) Sugar coating:
Sealing/Water proofing: provides a moisture barrier and harden the tablet surface.
Sub coating causes a rapid buildup to round off the tablet edges.
Grossing/Smoothing: smoothes out the sub coated surface and increases the tablet
size to Predetermine dimension. Coloring gives the tablet its color and finished size.
Polishing produces the characteristics gloss [48,49].
B) Film coating:
Film coating and the sugar coating share same equipment and the process
parameters. There are basically two methods of film coating they are Pan pour
methods: Tablets coated by pan pour method subjected to alternate solution
application, mixing and drying steps are similar to pan pour sugar coating. This
method is relatively slow and relies heavily on the skill of operator. Pan-spray
methods: The introduction of spraying equipment was the next evolution in improving
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the film coating process allows for automated control of liquid application. Broad flat
spray patterns are usually chosen by appropriate nozzle systems [50,51].
Spray dryer: Spray drying is a method of producing a dry powder from a liquid or
slurry by rapidly drying with a hot gas [52,53]. This is the preferred method of drying
of many thermally-sensitive materials such as foods and pharmaceuticals. A
consistent particle size distribution is a reason for spray drying some industrial
products such as catalysts. Air is the heated drying medium; however, if the liquid is
a flammable solvent such as ethanol or the product is oxygen-sensitive
then nitrogen is used. All spray dryers use some type of atomizer or spray nozzle to
disperse the liquid or slurry into a controlled drop size spray. The most common of
these are rotary disk and single-fluid high pressure swirl nozzles. Atomizer wheels
are known to provide broader particle size distribution, but both methods allow for
consistent distribution of particle size.[2] Alternatively, for some applications two-fluid
or ultrasonic nozzles are used. Depending on the process needs, drop sizes from 10
to 500 µm can be achieved with the appropriate choices. The most common
applications are in the 100 to 200 µm diameter range. The dry powder is often free-
flowing. The most common type of spray dryers are called single effect. There is a
single source of drying air at the top of the chamber (see n°4 on the diagram). In
most cases the air is blown in the same direction as the sprayed liquid (co-current).
A fine powder is produced, but it can have poor flow and produce a lot of dust. To
overcome the dust and poor flow of the powder, a new generation of spray dryers
called multiple effect spray dryers have been produced [54].
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Fig 1:9 Spray Drying Process
Encapsulation method:
Encapsulation relates to technologies which enable to formulate one active
compound (or more), inside individualized particles with a specific geometry and
properties. Encapsulation defines no size notion • Microencapsulation usually refers
to sizes ranging from 1 µm to 1 mm • Nanoencapsulation is used for nanometric
sizes but sometimes refers to sizes ranging up to 1 µm or few micrometers.
Methods: droplet extrusion (single or multi nozzle device, simple gravity, spinning
disk, jet breakage systems, co-extrusion) of a (bio)polymer solution in a gelation bath
or in ambient/cold air[55,56,57]. Particles properties (standard): Size range: from 50
µm to 7-8 mm,  Final state: wet (can be dried or lyophilized),  Active type: liquid,
solid; hydrophilic or lipophilic, Active content: up to 400 mg/g (wet), 900 mg/g (dry),
Structure: matrix, core / shell (s), (matrix core) / shell [58].
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Fig 1:10 Hydrogenation Method
Hydrogenation method:
Hydrogenation – to treat with hydrogen – is a chemical reaction between molecular
hydrogen (H2) and another compound or element, usually in the presence of a
catalyst such as nickel, palladium or platinum. The process is commonly employed
to reduce or saturate organic compounds. Catalytic hydrogenation has evolved into a
key process technology for the manufacture of pharmaceutical and fine chemicals,
replacing chemical reduction methods that generate large quantities of waste.
According to Roessler [1•], 10 to 20% of chemical reactions in fine chemical
synthesis at Roche are catalytic hydrogenations. Catalytic hydrogenations strike a
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balance among reaction kinetics, reactor design, catalyst activity and selectivity,
process control, mass transfer and mixing. Each of these factors contribute to the
performance of hydrogenation processes and their products [59,60,61,62].
Fig 1:11 Continuous Hydrogenation
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2. LITERATURE REVIEW
Y. Ankamma Chowdary, Ramakrishna Raparla, et al., (2014) reviewed on  the
present study, multilayered tablets of pioglitazone hydrochloride 15 mg and
metformin hydrochloride 500 mg were prepared in an attempt for combination
therapy for the treatment of type 2 diabetes mellitus. Pioglitazone HCl was
formulated as immediate release layer to show immediate action by direct
compression method using combination of superdisintegrants, namely, crospovidone
and avicel PH 102. Crospovidone at 20% concentration showed good drug release
profile at 2 hrs. Formulation F13 showed 99.97% of pioglitazone release at 2 hrs in
0.1 N HCl and metformin showed 98.81% drug release at 10 hrs of dissolution in
6.8 pH phosphate buffer. The developed formulation is equivalent to innovator
product in view of in vitro drug release profile. The results of all these evaluation
tests are within the standards. The procedure followed for the formulation of these
tablets was found to be reproducible and all the formulations were stable after
accelerated stability studies. Hence, multilayered tablets of pioglitazone HCl and
metformin HCl can be a better alternative way to conventional dosage forms.
Karthik Varma V (2016) the study focus on excipients are additive substances used
in tablet formulation to improve bulkiness, disintegration, dissolution rate and
bioavailability of the drug. The drug and excipient interaction study is carried using
Infrared Spectrum to know the stability of excipients and drug.
D.Banerjee, R. Singh et al ., (2016) This review on purpose of this study was to
formulate Cefpodoxime Proxetil compression-coated tablets for gastroretentive drug
delivery. In this the core tablet is formulated to be retained in the stomach for a
period of approximately 12 hrs using different polymer blend. The core tablet has half
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the amount of the drug and the rest of the drug in the coating layer. This outer layer
is so formulated to release its drug content in a period of 15mins so as to achieve the
initial burst release and then after 2 hours as the plasma concentration of the drug
decreases then the core layer starts releasing its drug content so that the plasma
concentration of the drug is maintained in the therapeutic window for the duration of
12 hrs. Thus the dosing interval is increased from 4 hrs to 12hrs. The batches are
optimized using the factorial designing. Also the formulation is evaluated for its
release profile and compared with the other standard release profiles.
Surya Bhan Singh Rathore, Anshu Sharma, etal.,(2013) The present study was
an attempt to formulate and evaluate enteric coated tablets for Ilaprazole to reduce
the gastrointestinal tract side effects. Four formulations of core tablets were prepared
and one who shows rapid disintegration (near around three minutes) was selected
for enteric coating. Ilaprazole which have an irritant effect on the stomach can be
coated with a substance that will only dissolve in the small intestine. Enteric coat was
optimized using two different polymers such as HPMCP 50 and Eudragit L 100 in
different concentrations. The prepared tablets were evaluated in terms of their pre-
compression parameters, physical characteristics and in-vitro release study. 2.5%
seal coating on core tablets was optimized and 9% enteric coating on seal coated
tablets was performed using HPMC P 50 (60%), triethyl citrate (10%) and IPA:DCM
(60:40) which gives the highest dissolution release profile and f2 value.
Himanshu.K.Solanki et al., (2010) Granulation is one of the most important unit
operations in the production of pharmaceutical oral dosage forms. Granulation
process will improve flow and compression characteristics, reduce segregation,
improve content uniformity, and eliminate excessive amounts of fine particles. The
results will be improved yields, reduced tablet defects, increased productivity, and
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reduced down time. Pharmaceutical products are processed all over the world using
the direct-compressing, wet-granulation, or dry granulation methods. Which method
is chosen depends on the ingredients individual characteristics and ability to properly
flow, compresses, eject, and disintegrate. Choosing a method requires thorough
investigation of each ingredient in the formula, the combination of ingredients, and
how they work with each other. Then the proper granulation process can be applied.
The objective of present article was to focus on the novel granulation technology.
Singh Deep Hussan*, Roychowdhury Santanu, et al.,(2012) this study evaluate
enteric coated tablets are solid unit dosage forms which are designed to bypass the
stomach and release the drug in small intestine and are meant for oral
administration. The word “enteric” indicates small intestine; therefore enteric coatings
prevent release of medication before it reaches the small intestine. Most enteric
coatings work by presenting a coated surface that is stable at the highly acidic pH
found in the stomach, but breaks down rapidly at a less acidic (relatively more basic)
pH. Materials used for enteric coatings include CAP, CAT, PVAP and HPMCP, fatty
acids, waxes, shellac, plastics and plant fibers. The present review describes enteric
coating, their ideal properties, benefits and limitation, various polymers used, their
chemical structure, criteria for drug selection and mechanism, methods of
manufacturing and evaluation of enteric coated tablets. Recently, these have
attracted the interest of many formulators due to their advantages over the
conventional drug delivery systems as they prolong the dosing intervals and also
increase patient compliance. The study provides an overview of the recent advances
that have taken place in this arena.
Shrivastava Priyanka and Sethi Vandana., (2013), A Review article on:
Superdisintegrants. Disintegration plays a major role in improving the drug activity
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and hence increases the patient compatibility. The therapeutic activity of the
formulations is obtained by disintegration followed by dissolution. Disintegrants are
the substances that causes the rapid disintegration of the capsules or tablets into
smaller particles that dissolves more rapidly than in the absence of the disintegrants.
On the other hand super disintegrants, as it name suggests superior to disintegrants
are the substances which facilitates or increases the disintegration time even at low
level ,typically 1-10% by weight relative to the total weight of the dosage unit. This
article comprises of study of superdisintegrants which are being used in the
formulation to provide safe and effective drug delivery with improved patient
compliance.
Amit A. Patel et al., (2012), Formulation and evaluation of doxycycline
hydrochloride delayed release enteric coated tablets. The present study was
undertaken with an aim to formulate doxycycline hydrochloride delayed release
tablets. Successful delivery of drugs specifically to the intestine requires the
protection of drug from being released in stomach. This drug is universal antibiotic
and can be targeted to the specific site of absorption by enteric coating using pH
dependant polymers. The present study demonstrates that the doxycycline
hydrochloride compression coated tablets could be targeted to intestine using pH
dependent polymers. Enteric coating was carried out using different polymers like
Eudragit L-30 D-55, hydroxy propyl methylcellulose phthalate, cellulose acetate
phthalate and acryl-EZE® to achieve 5% weight gain and 9 % weight gain. This was
concluded that formulation containing Eudragit L 30 D 55 remain intact in 0.1 N HCl
and dissolve fast in pH 6.8 phosphate buffer.and shows better results compare to the
formulation containing hypromellose phthalate and cellulose acetate phthalate.
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Ahuja Naresh et al., (2012), this review on development of hpmcp based aqueous
enteric coating polymer. The advantages of an aqueous-based coating system have
been recognized. This is derived from the drawbacks of organic solvents, including
pollution, explosion hazards and solvent toxicity. Especially, there are risks for
operators. For these reasons, water based systems are now gradually being applied
instead of organic coating systems. The objective of current study is to develop a
HPMCP based enteric coating material which satisfy the need of enteric coating and
contains the advantages of aqueous coating material.
Ajit Patil et al., (2011), Formulation and evaluation of enteric coated tablets for
azithromycin dihydrate to reduce the Gastrointestinal tract side effects.Three
formulations of core tablets were prepared and one whoshows rapid disintegration
(below three minutes) was selected for enteric coating . Enteric coat was employed
by usingdifferent polymers such as HPMC-55, Eudragit, Ethyl cellulose in different
ratios Combination of HPMC-55 and ethylcellulose (10:1.5) exibited better
dissolution ,disintegration, hardness and friability properties .This study concluded
that enteric coated tablets of azithromycin dihydrate can be prepared by using
combination of polymers studied and we can reduce the GI tract side effects.
Tsung Yueh Tsai et al., (2011), Effect of diluents on the swelling force of the tablet.
The swelling force, especially the swelling force development rate, is a very
important parameter in studying the effect of a disintegrant in a tablet. However, a
tablet also contains diluents in most cases and the effect of diluents on the swelling
force has not been studied. In this study two commonly used diluents,
microcrystalline cellulose and calcium phosphate dihydrate, were investigated for
their effect on the swelling force with or without a superdisintegrant, Polyplasdone
XL. It was found that microcrystalline cellulose alone can develop swelling force
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depending on the compression force of the tablet. When combined with
Polyplasdone XL, it can significantly change the swelling force of Poly plasdone XL.
Their results reveals that Depending on the nature, the diluent can display the
swelling force or not. Di-tab doesn’t show any swelling force but Avicel shows varied
degrees of swelling force depending on the compression force. Avicel alone shows
gradual force development. With Di-tab added a plateau appears quickly.
Nobutomo Ikarashi et al., (2011), The Laxative Effect of Bisacodyl is attributable to
decreased aquaporin-3 expression in the colon induced by increased PGE2
secretion from macrophages. This study was to investigate the role of aquaporin3
(AQP3) in the colon in the laxative effect of bisacodyl. After oral administration of
bisacodyl to rats, AQP3, macrophages, cyclooxygenase 2 (COX2), and
prostaglandin E2 (PGE2) were examined in the colon. Aquaporins are integral
membrane proteins from a larger family of major intrinsic proteins (MIP) that form
pores in the membrane of biological cells.Genetic defects involving aquaporin genes
have been associated with several human diseases. From the results suggest that
bisacodyl may decrease the expression of AQP3 in the colon, which inhibits water
transfer from the luminal to the vascular side and leads to a laxative effect.
AppaRao. B et al., (2010), Formulation and Evaluation of Aceclofenac Solid
Dispersions for Dissolution Rate Enhancement. Aceclofenac is a novel non-steroidal
antiinflammatory drug (NSAID) having anti-inflammatory and analgesic properties,
and is widely used in the treatment of rheumatoid arthritis, osteoarthritis, and
ankylosing spondylitis. One of the major problems with this drug is its low solubility in
biological fluids, which results into poor bioavailability after oral administration.
Therefore, solid dispersions (SDs) of Aceclofenac were prepared using lactose,
mannitol and urea to increase its aqueous solubility. Aceclofenac SDs was prepared
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in 9:1, 7:3 and 4:1 ratios of the drug to polymer (by weight). In vitro release profiles
of all SDs preparations were comparatively evaluated and also studied against pure
Aceclofenac. Faster dissolution was exhibited by solid dispersion containing 9:1 ratio
of drug: lactose. The increase in dissolution rate of the drug may be due to increase
in wettability, hydrophilic nature of the carrier and due to reduction in drug
crystallinity.
Rupesh S. Kamble et al., (2010), Formulation and Development Of Enteric Coated
Dosage Form Using Ketorolac Tromethamine to reduce the side effects while
prolonging its action by using controlled release of oral dosage forms is highly
desirable. In the present study direct compression method is used for the preparation
of fabricated batches and EudragitL100 is used as coating polymer for enteric
coating. In vitro release profiles of batches F1-F4 shows that Ketorolac Tro
methamine drug:polymer ratio with Guar gum, Xanthan Gum, Ethyl cellulose and
Sodium alginate give 79.32%, 91.52%, 88.35% and 92.19% drug release
respectively in 12 hours. In vitro release profile of batches F5-F8 shows 85.21%,
95.52%, 93.50%, 97.24% respectively in 12 hours. In vitro release profile of batches
F9-F12 shows that Ketorolac Tromethamine in ratio 1:3 with Guar gum, Xanthan
Gum, Ethylcellulose and Sodium alginate gives release of 89.50%, 98.25%, 95.22%,
100.27% respectively in 12hours. And then showed higher increase in phosphate
buffer of pH 6.0 up to 12 hours. All these batches follow near zero order kinetics.
This indicates that the Guar Gum, Xanthan Gum and Ethyl cellulose and Sodium
alginate at minimum concentration is not only able to sustain but also control the
drug release.
Tansel Comoglu., (2010), Effects Of Compression Speed And Lubrication On The
Compaction Properties Of Some Commonly Used Direct Compression Materials.
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This study was to investigate the effects of punch speed and lubrication (with and
without the addition of 1% magnesium stearate) on the compaction properties of
three different classes of excipients; microcrystalline cellulose (Avicel PH 101),
pregelatinized starch (Starch 1500) and dibasic calcium phosphate (Fujicalin) having
plastic, elastic and brittle fragmentation characteristics were evaluated. The three
different speeds were investigated 10, 50 and 100 mm/sec. From the data observed,
plastic materials like Avicel PH 101 form harder tablets at low compression speeds
whereas brittle fragmenting materials like Fujicalin were relatively unaffected by
compaction speed. Avicel PH 101 gave the hardest tablets at all compression
speeds with and without the addition of lubricant. It is concluded that because of its
plastic deformation under pressure, Avicel PH 101 perform as a binder whereas both
fragmentation and plastic deformation take place in Starch 1500.
V. P. Pandey et al,. (2009), Studies On Diluents For Formulation Of Tablets. Tablet
remains popular as a dosage form because of the advantages afforded both to the
manufacturer (e.g. Simplicity and economy of preparation, stability and convenience
in packing, shipping, and dispensing) and the patient (accuracy of dose,
compactness, baldness of taste and ease of administration). Tablet formulation may
contain diluent to provide better tablet properties such as improved cohesion, direct
compression manufacturing and to promote flow properties. In this study, lactose
monohydrate, dibasic calcium phosphate (DCP) and microcrystalline cellulose
phosphate (MCCP) were studied as diluents in the same quantity for manufacture of
chloroquine phosphate tablet using polyvinyl pyrrolidone K-30 (PVP K-30) as binding
agent and sodium starch glycolate (S.S.G.) as disintegrating agent. It was concluded
that formualtion containing lactose monohydrate as diluent produces 87.12% drug
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release in 45 minutes. So lactose monohydrate is considered as suitable diluent for
formulating this drug.
Amitava Roy et al., (2009), Effects of plasticizers and surfactants on the film
forming properties of hydroxypropyl methylcellulose for the coating of diclofenac
sodium tablets. In this work, hydroxy propyl methyl cellulose (HPMC) 5cPs, an
aqueous soluble polymer was employed for coating diclofenac sodium (DFS) tablets
25 mg for protecting the integrity of the drug yet rendering the drug to release at a
faster rate on contact with the gastric environment. The defect free selected
formulations were further subjected for studying the effects of surfactants like sodium
lauryl sulphate (SLS) and Tween-80 along with the plasticizers. The quality of the
aqueous film coats or the plasticizer efficiency in case of PEG-400 is in the order
1.5> 0.5> 1.0% and for PG 1 > 4 > 3% which can be stated on the basis of less
incidence of major coat defects like chipping, cracking, orange peel, roughness,
blistering, blooming, picking. The quality of aqueous film coat or the surfactant
efficiency in case of SLS + PEG-400 is in the order 0.3< 0.5< 0.1% and SLS + PG is
in the order 0.5< 0.1< 0.3%. In case of Tween-80 +PEG-400 the order is 0.3 < 0.1%
and Tween-80 + PG is in the order 0.3< 0.1< 0.5%. They concluding that tablet
coating films made of HPMC 5cPs with the addition of PEG at 1.5% and SLS at
0.3% and films made of HPMC 5cPs with PG at 1% and Tween-80 at 0.3% could be
considered as an elegant film forming formulation for solving different coating
problems.
European Patent Specification., (1995), Bisacodyl Dosage Form: This subject
invention involves pharmaceutical compositions in dosage unit form, for peroral
administration of bisacodyl to a human or lower animal having a gastrointestinal
tract, with a lumen there through, with a small intestine and a colon with a junction
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there between, comprising: (a) a safe and effective amount of rapidly-dissolving
bisacodyl means; and (b) a delivery means which completely surrounds and encases
the bisacodyl means in the dosage unit form prior to oral administration and which
prevents the release of bisacodyl from the dosage form into the lumen of the
gastrointestinal tract during transport of the dosage form through the lumen until the
dosage form is near the junction between the small intestine and the colon or in the
colon, and which then releases the bisacodyl in the lumen near the junction between
the small intestine and the colon or within the colon.
Eija Leskinen., (2003), Tablet disintegration: Effects of temperature and pH of
aqueous disintegrating fluid and influence of solubility of diluent on the behaviour of
superdisintegrants. In the experimental work three grades of lactose were combined
with foursuperdisintegrants and tablets were prepared with different porosity levels.
Also one hygroscopic and insoluble diluent, sorbitol and dicalcium phosphate
dihydrate were used in combination with disintegrants. Disintegration and
calorimetric measurements were made in three temperatures with water and
simulated gastric and intestinal fluid. Investigations show that superdisintegrants
have a greater effect on disintegration time in an insoluble system than in a soluble
or partially soluble system. It is concluded that results showed that the choice of
tablet excipients can have a great influence in disintegration time. As the dissolution
of drug is dependent on the disintegration rate of tablet, it is thus important to pay
attention to diluent and disintegrant used in order to achieve the desired availability
for the drug.
Rajnikant C.Patel., (2009), Formulation Strategies For Improving Drug Solubility
Using Solid Dispersions. The solubility is the biggest challenging aspects for most of
the drugs in develpoing the tablets. Solid dispersions have been employed to
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enhance the dissolution rates of poorly water - soluble drugs. This work is based on
the various solubility enhancement strategies in solid dispersion. The approaches
described are fusion (melting), solvent evaporation, lyophilization (freeze drying),
melt agglomeration process, extruding method, spray drying technology, use of
surfactant, electro static spinning method and super critical fluid technology and also
highlights the potential applications and limitations of these approaches. They
concludes solid dispersion method is one of the effective approaches to achieve the
goal of solubility enhancement of poorly water-soluble drugs.
Eija Leskinen., (2003), Tablet disintegration: Effects of temperature and pH of
aqueous disintegrating fluid and influence of solubility of diluent on the behaviour of
superdisintegrants. In the experimental work three grades of lactose were combined
with foursuperdisintegrants and tablets were prepared with different porosity levels.
Also one hygroscopic and insoluble diluent, sorbitol and dicalcium phosphate
dihydrate were used in combination with disintegrants. Disintegration and
calorimetric measurements were made in three temperatures with water and
simulated gastric and intestinal fluid. Investigations show that superdisintegrants
have a greater effect on disintegration time in an insoluble system than in a soluble
or partially soluble system. It is concluded that results showed that the choice of
tablet excipients can have a great influence in disintegration time. As the dissolution
of drug is dependent on the disintegration rate of tablet, it is thus important to pay
attention to diluent and disintegrant used in order to achieve the desired availability
for the drug.
Masaaki Nakahara, Akihiko Kurosaki, et al… (2009) have clearly demonstrated
the conventional methods for powdering oil-soluble substance mentioning their
common drawbacks. They discovered that elution of the same to heat, pressure,
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water, or the like, can be prevented by allowing the same to adsorb on a calcium
component in an aqueous solution in the presence of surfactant.
Gregory Paul (2007) Dittmar Andrew Irvine Sokolik in their patent application title
“Vitamin D content uniformity in pharmaceutical dosage forms” have come up with
new dosage forms of vitamin D3 and calcium carbonate having improved content
uniformity. The improvements are realized through modifications to the formulation,
the raw material specifications, and the process of manufacture (6).
Vladimir Babtsov, Kiryat Shmona, etal., (2005) in their patent article “Methods of
Microencapsulation” have used excipients like polymethylacrylate, cellulose acetate,
polyvinyl alcohol, sodium Lauryl acetate etc in their preparation involving
Microencapsulations of water insoluble drugs.
Hahnlein, Wolfgang, etal.. (2003) have prepared a dry emulsion preparation of
vitamin D3 by homogenizing vitamin D3 in an aqueous solution containing one of
more protective colloids for a time and under conditions effective to produce an
emulsion containing vitamin D3. They said aqueous solution optionally contains one
or more sugars or other additives and drying the mixture optionally in the presence of
a coating material, to yield a dry powder.
Yajima and Mizuo (1990) have demonstrated the powdering of vitamin D3 by spray
drying a method that involves addition of the vitamins to a solvent and agitation. The
solvent is removed and the residue is subjected to powdering. The powdering may
be effected by spray drying, drying in vacuum, freeze-drying in drum of other know
drying methods. They concluded that when a diluted acid is used as a solvent, the
pH  Should preferably be adjusted to 3 to 4. On the contrary, when diluted ammonia
is used, the pH should preferably adjust to 10-11. Subsequently, vitamins are added.
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Makino, Yuji Suzuki, etal.., (1996) have introduced a pharmaceutical solid
preparation of active form of vitamin D3 of improved stability which comprises of
active form of vitamin D3 dispersed in an excipient readily soluble in organic solvent
and a basic substance. They also examined the stability and ‘residual percentage of
active vitamin D3’ of the prepared specimen comparing with the control (standard
vitamin D3).
Ishii, Kuniaki, Toriumi, etal... (1994) have prepared solid pharmaceutical
preparations containing a vitamin D3 derivative. The composition of this preparation
consisted of excipients like Mannitol, sugar, Hydroxypropyl cellulose, and a binder
polyvinyl pyrrolidone.
Moroi, Masami, etal… (1993) have demonstrated the methid, for the preparation of
a stable dosage-form of active vitamin D3, which comprises an active vitamin D3 and
a stabilizer selected from polyvinylacetal diethylaminoacetate and
Hydroxypropylcellulose adding a pharmaceutically-acceptable carrier to the resultant
mixture (12).
Nemoto, Kaoru, etal… (1989) in their patent article “Stabilized active forms of
vitamin D3” demonstrated the preparation containing an active form of vitamin D3
which is stabilized by incorporation of an amino acid. They concluded amino acids
that do not contain a sulphur atom or an acid amino group in its structure stabilized
the vitamin D3.
John M. Ballard, LImin Zhu, etal.. (2007) conducted LC-UV profile of a thermally
stressed vitamin D3 tablet and concluded that four major degradants formed are
identified as the Octanoate and Decanoate esters of D3 and pre-vitamin D3. This
observation reinforces the need to be aware of potential interactions when designing
Department of Pharmaceutics AKCP
L
IT
E
R
A
T
U
R
E
R
E
V
IE
W
29
formulations of apparently inert excipients and active pharmaceutical ingredients.
They also concluded that even minor drug-excipent reactivity can be significant in
the long-term stability of pharmaceutical products due to the stringent quality
standards to which pharmaceutical formulations are held.
Semih Otles, Yasar Hisil (1994) have clearly demonstrated the determination of
vitamin D3 by high pressure liquid chromatography (HPLC). They estimated the
quantity of vitamin D3 in hen egg and the recovery study of vitamin D3. They finally
concluded that HPLC method is rapid simple, sensitive, reproducible and very
efficient technique for the determination of vitamin D3 in hen eggs.
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3. DRUG PROFILE
VITAMIN D3
Cholecalciferol, also known as vitamin D3 and colecalciferol, is a type of vitamin
D which is made by the skin, found in some foods, and taken as a dietary
supplement.
Chemical Formula
C27H44O
Chemical Name
5Z,7E)-9,10-secocholesta-5,7,10 (19)-trien-3ß-ol
Molecular Weight
384.64
Synonyms
Calciol, CC, Colecalciferol, Colecalciferolum
CAS number
67-97-0
IUPAC Name
(1S,3Z)-3-{2-[(1R,3aS,4E,7aR)-7a-methyl-1-
[(2R)-6-methylheptan-2-yl]-octahydro-1H-inden-4-
ylidene]ethylidene}-4-methylidenecyclohexan-1-ol
Absorption
Readily absorbed
Volume of distribution
Not Available
Protein binding
50% to 80%
Department of Pharmaceutics AKCP
D
R
U
G
 P
R
O
F
IL
E
31
Indication
For the treatment of vitamin D deficiency or
insufficiency, refractory rickets (vitamin D resistant
rickets), familial hypophosphatemia and
hypoparathyroidism, and in the management of
hypocalcemia and renal osteodystrophy in
patients with chronic renal failure undergoing
dialysis. Also used in conjunction with calcium in
the management and prevention of primary or
corticosteroid-induced osteoporosis
Pharmacodynamics
cholecalciferol (vitamin D3) is a steroid hormone
that has long been known for its important role in
regulating body levels of calcium and phosphorus,
in mineralization of bone, and for the assimilation
of Vitamin A. The classical manifestations of
vitamin D deficiency is rickets, which is seen in
children and results in bony deformaties including
bowed long bones. Deficiency in adults leads to
the disease osteomalacia. Both rickets and
osteomalacia reflect impaired mineralization of
newly synthesized bone matrix, and usually result
from a combination of inadequate exposure to
sunlight and decreased dietary intake of vitamin
D. Common causes of vitamin D deficiency
include genetic defects in the vitamin D receptor,
severe liver or kidney disease, and insufficient
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exposure to sunlight. Vitamin D plays an important
role in maintaining calcium balance and in the
regulation of parathyroid hormone (PTH). It
promotes renal reabsorption of calcium, increases
intestinal absorption of calcium and phosphorus,
and increases calcium and phosphorus
mobilization from bone to plasma
Mechanism of Action The first step involved in the activation of vitamin
D3 is a 25-hydroxylation which is catalysed by the
25-hydroxylase in the liver and then by other
enzymes. The mitochondrial sterol 27-hydroxylase
catalyses the first reaction in the oxidation of the
side chain of sterol intermediates. The active form
of vitamin D3 (calcitriol) binds to intracellular
receptors that then function as transcription
factors to modulate gene expression. Like the
receptors for other steroid hormones and thyroid
hormones, the vitamin D receptor has hormone-
binding and DNA-binding domains. The vitamin D
receptor forms a complex with another
intracellular receptor, the retinoid-X receptor, and
that heterodimer is what binds to DNA. In most
cases studied, the effect is to activate
transcription, but situations are also known in
which vitamin D suppresses transcription.
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Calcitriol increases the serum calcium
concentrations by: increasing GI absorption of
phosphorus and calcium, increasing osteoclastic
resorption, and increasing distal renal tubular
reabsorption of calcium. Calcitriol appears to
promote intestinal absorption of calcium through
binding to the vitamin D receptor in the mucosal
cytoplasm of the intestine. Subsequently, calcium
is absorbed through formation of a calcium-
binding protein
Metabolism
Within the liver, cholecalciferal is hydroxylated to
calcidiol (25-hydroxycholecalciferol) by the
enzyme 25-hydroxylase. Within the kidney,
calcidiol serves as a substrate for 1-alpha-
hydroxylase, yielding calcitriol (1,25-
dihydroxycholecalciferol), the biologically active
form of vitamin D3
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Cholecalciferol was first described in 1936. It is on the World Health Organization's
List of Essential Medicines, the most effective and safe medicines needed in a health
system. The wholesale cost in the Costa Rica is about 2.15 USD per 30 ml bottle of
10,000 IU/ml. In the United States treatment costs less than 25 USD per month.
Fig: 12 The three steps in the synthesis and activation of vitamin D3 are
regulated as follows:
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 Cholecalciferol is synthesized in the skin from 7-dehydrocholesterol under the
action of ultraviolet B (UVB) light. It reaches an equilibrium after several minutes
depending on the intensity of the UVB in the sunlight - determined by latitude,
season, cloud cover, and altitude - and the age and degree of pigmentation of
the skin.
 Hydroxylation in the endoplasmic reticulum of liver hepatocytes of cholecalciferol
to calcifediol (25-hydroxycholecalciferol) by 25-hydroxylase is loosely regulated,
if at all, and blood levels of this molecule largely reflect the amount of
cholecalciferol produced in the skin combined with any vitamin D2 or D3 ingested.
 Hydroxylation in the kidneys of calcifediol to calcitriol by 1-alpha-hydroxylase is
tightly regulated: it is stimulated by parathyroid hormone and serves as the major
control point in the production of the active circulating hormone calcitriol (1,25-
dihydroxyvitamin D3).
MAGNESIUM GLYCINE COMPLEX
Magnesium glycine complex is a mineral supplement advised nowadays to treat low
amounts of magnesium in the blood. Magnesium is an essential micronutrient which
plays a key role in the functioning of muscles, nerves, heart and bones.
Table  3:1 Magnesium glycine complex
S.No Magnesium glycine complex
1. Magnesium
2. Lead
3. Arsenic
4. Mercury
5. Cadmium
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Magnesium glycinate is often used because it is the best-absorbed form of
magnesium.
Table  3:2 Magnesium glycine complex
Name Magnesium Glycinate
Chemical Formula C4H8MgN2O4
IUPAC Name magnesium(2+) ion bis(2-aminoacetate)
Type  Small Molecule
Description  Magnesium glycinate is a magnesium salt of
glycine that is available as dietary
supplements as a source of magnesium. It is
used in the treatment of magnesium
deficiency.
CAS number 14783-68-7
Synonyms Not available
 In Osteoporosis: Magnesium plays a role in the development of healthy bones, and
people with higher levels of magnesium may have a higher bone mineral density.
This is important in helping to reduce the risk of bone fractures and osteoporosis.
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EXCIPIENT PROFILE
POVIDONE K30
Synonyms : polyvinylpyrrolidone (PVP) , polyvidone
Description : Povidone occurs as a fine, white to creamy white colored,
odourless oral most odourless, hygroscopic powder.
Functional category : It is used as a binder in many pharmaceutical tablets and
used in many technical applications with various roles such as an adhesive, additive,
and emulsifier. It also has disinfectant properties.
Applications In Pharmaceutical Formulation Or Technology
Povidone solutions are used as binders in wet-granulation processes. Povidone is
also added to powder blends in the dry form and granulated in situ by the addition of
water, alcohol, or hydro-alcoholic solutions.
CROSPOVIDONE
Synonyms : Poly vinyl pyrolidone, crospovidone,povidone
Chemical name : C6H9NO
Descriptions : White color fine powder, tasteless, odourless
Functional categories : Disintegrating agents
Solubility : Insoluble in PVP, Soluble in water
Melting point : 1500c
Stability and storage condtions : Stored in a well closed container in a cool place.
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MICROCRYSTALLINE CELLULOSE
Non-proprietary : BP/ JP /USPNF : Microcrystalline cellulose
PhEur : Cellulosum microcristallinum
Synonyms : Avicel PH, Celexe, Cellulose gel, Celphere, Ceolus KG,
Crystalline cellulose, Emcocel, Ethispheres, Fibrocel,
Pharmacel, Tabulose, and Vivapur.
Chemical Name : Cellulose.
Description : Colour : White.
Nature : Crystalline powder composed of porous particles.
Typical Properties : Angle of repose : 49° for Ceolus KG.
Density (bulk) : 0.337 gm/cm3.
Functional Category : Adsorbent, suspending agent, tablet and capsule diluent,
tablet disintegrant.
Table 3:3 Applications MCCPpH102 in Pharmaceutical Formulation
Use Concentration
Adsorbent 20–90
Adherent 5–20
Capsule binder/diluents 20–90
Tablet disintegrant 5–15
Tablet binder/diluent 20–90
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COLLOIDAL SILICON DIOXIDE:
Non-proprietary Names : BP : Colloidal anhydrous silica
PhEur : Silica colloidalis anhydrica
USPNF : Colloidal silicon dioxide
Synonyms : Aerosil, Cab-O-Sil, Cab-O-Sil M-5P, colloidal silica,
fumed silica, light anhydrous silicic acid, silicic
anhydride, silicon dioxide fumed, Wacker HDK.
Chemical Name : Silica
Description : Colour: Bluish-White.
Nature : Nongritty amorphous, particle size: 15 nm.
Typical Properties : Acidity/alkalinity: pH = 3.5–4.4 (4% w/v aqueous
dispersion) Bulk Density : 0.029–0.042 g/cm3 Carr’s
index : 35.52% Solubility: Practically insoluble in
organic solvents, water, and acids, except hydrofluoric
acid, soluble in hot solutions of alkali hydroxide.
Forms a colloidal dispersion with water.
Functional Category : Adsorbent, Anticaking agent, Emulsion stabilizer, Glidant,
Suspending agent, Tablet disintegrant, Thermal
stabilizer, Viscosity-increasing agent.
Talc Synonyms : Talcum powder, Soaprock, Talc, French chalk,
Steatite Chemical
Formula : Mg3Si4O10 (OH)2
Descriptions : Colorless
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Functional categories : Lubricant
Solubility : Insoluble in water, slightly soluble in dilute mineral
acids
Melting point : 15000c
Molecular weight : 379.259 g/mol
MAGNESIUM STEARATE
Synonyms : Dolomol, Magnesium Stearate
Chemical formula : Mg(C18H35O2)2
Descriptions : White color
Functional categories : Lubricant
Molecularweight : 591.27 g/mol
Solubility : Soluble in Water, Slightly Soluble in Benzene
Melting point : 88.50C
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4. AIM AND OBJECTIVES
AIM :
Aim of present study is investigated formulation development and evaluate of
Vitamin D3. Research is focused to improve the stability of the drug by changing the
production process meant for the treatment of  rickets, familial hypophosphatemia
and hypoparathyroidism, and in the management of hypocalcemia and renal
osteodystrophy in patients with chronic renal failure undergoing dialysis,calcium in
the management and prevention of primary or corticosteroid-induced osteoporosis.
OBJECTIVES :
 To formulate development and evaluate food drug product of  Vitamin D3
 To study the disintegration time and coating technology of tablet.
 To study the stability of the formulated drug.
The Pharmaceutical Formulation objectives which were destined to achieve during
the work are:
 Stability of the tablet with good physical strength with long period of time.
 Tablets with optimum content of active pharmaceutical ingredients without
variation in the content unit/tablet.
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5. MATERIAL AND METHOD
Table No 5:1 List of materials:
S.No Raw Materials Manufacture
1. Cholecalciferol
Vitamin D3
Spansules pharmatech
2. Magnesium Glycine Complex Coral Calcium
3. Mannitol Shandong Tianl
4. Sodium Starch Glycolate Amishi Drugs/J.R. Pharma
5. Microcrystaline Cellulose Amit hydrocolloids/Akash Pharma
6. Povidone Jiaozuo Yuanhai/Boai NKY
Pharmaceuticals
7. Povidone Jiaozuo Yuanhai
8. Crospovidone JH Nan hang
9. Microcrystalline Cellulose Juku orchem/Amishi
10. Colloidal silicone di oxide Cabot Sanmar/ Henan Xunyu
Chemical
11. Talc Gangotri/ Neelkanth
12. Erythrosine Lake Neelikon Foods dyes
13. Brilliant Blue Lake Neelikon Foods dyes
14. Isopropyl Alcohol Deepak Fertilizers/ Lee Chang
Yuang
15. Methylene Chloride Chemplast/Gujarat Fluoro
Chemicals
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Table No 5:2 Equipment used for formulation
S.NO EQUIPMENT MAKE
1. Laminar Air Flow – Dispensing booth Micro Flow
2. Electrical Balance LCGC
3. Vibro Sifter – 1 & 2 Gem Pharma Machineries
4. Paste Preparation Kettle Gem Pharma Machineries
5. Ribbon Mixture Gem Pharma Machineries
6. Rapid Mixer Gem Pharma Machineries
7. Tray Drier Gem Pharma Machineries
8. Fluid Bed Drier Gem Pharma Machineries
9. Multi mill Gem Pharma Machineries
10. Mobile Loader Gem Pharma Machineries
11. Compression Machine – 16/27 station Cadmach Machinery
12. Tablet in Tablet Compression
Machine
Cadmach Machinery
13. Tablet De–Duster – 1,2&3 Fluid Pack
14. Analytical Balance LCGC
15. Disintegration Apparatus Electro Lab
16. Friability Apparatus Electro Lab
17. Hardness Tester In Lab
18. Digital Vernier Caliber – 1,2&3 Mitutoyo
19. Tap Density Apparatus Electro Lab
20. IR Moisture Analyser LCGC
21. Manual Coating Machine Gem Pharma Machineries
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22. Auto Coater Neo Cota
23. Colloid Mill Gem Pharma Machineries
24. Tablet Inspection Conveyor Gem Pharma Machineries
25. Metal Detector United Engineering
Pre-formulation studies:
Pre-formulation testing is an investigation of physical and chemical properties of
a drug substance alone and when combined with excipients. It is the first step in the
rationale development of dosage forms. Pre-formulation studies yield necessary
knowledge to develop suitable formulation. It gives information needed to define
nature of drug substance and provide a dosage form. Hence, the following pre-
formulation studies were performed for the obtained sample of drug.
 Organoleptic evaluation
 Angle of repose
 Bulk density
 Tapped density
 Compressibility index
 Hausner’s ratio
 Solubility studies
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Organoleptic evaluation:
The organoleptic property of
 Color
 Taste
 Odor
 Flavor
Angle of repose:
The angle of repose is the maximum angle of a stable slope determined by
friction, cohesion and the shapes of the particles. When bulk granular materials are
poured onto a horizontal surface, a conical pile will form. The internal angle between
the surface of the pile and the horizontal surface is known as the angle of repose
and is related to the density surface area, and coefficient of friction of the material.
Material with a low angle of repose forms flatter piles than material with a high angle
of repose [63].
Angle of repose was determined using funnel method. The height of the funnel
was adjusted in such a way that the tip of the funnel just touches the heap of the
blends. Accurately weighed blend is allowed to pass through the funnel freely on to
the surface. The height and diameter of the powder cone was measured and angle
of repose was calculated using the following equation,
ᶿ = tan-1(h/r)
ᶿ = angle of repose
h = height of pile
r = radius of pile
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Table No 5:3 Flow property of angle of repose:
S.No Flow property Angle of repose
1. Excellent 25-30
2. Good 31-35
3. Fair 36-40
4. Passable 41-45
5. Poor 46-55
Bulk density:
Bulk density is ratio of given mass of powder and its bulk volume. Bulk density
was determined by measuring the volume of known mass of powder sample that has
been passed through the screen in to granulated cylinder or through volume
measuring apparatus into cup [64].
Bulk density = M/V0
Where, M = Mass of the powder
V0 = bulk volume of the powder.
Limits: It has been stated that the bulk density values having less than 1.2g/cm3
indicates good packing and values greater than 1.5g/cm3 indicates poor packing.
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Tapped density:
A known quantity of powder was transferred to a graduated cylinder and volume
V0 was noted. The cylinder fixed to a density determination apparatus, tapped for
500 times then reading was observed. The density is achived by mechanically
tapped by a measuring cylinder containing the powder sample. After observing the
initial volume the cylinder is mechanically tapped and volume reading were taken
until little further volume changes is observed [65].
Tapped density = M/Vr
Where,
M = Mass of the powder
Vr = final tapping volume of the powder
Compressibility index and Hausner ratio:
The compressibility index and Hausner ratio may be calculated using measured
values of bulk density and tapped density as follows[66],
Compressibility index = 100 × tapped density/bulk density
Hausner ratio = tapped density/bulk density.
Solubility studies :
The solubility of Vitamin D3 in solvents was observed to decrease in the order of
Propan-1-ol  > Ethanol > Ethyl Ethanoate > Propan-2-one > Methanol > Ethanenitrite
[67].
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Compressed Tablet
Description:
Blue coloured, caplet shaped film coated tablets  with plain on both sides
Weight Variation:
Twenty tablets were selected randomly and the average weight was determined
using an electronic balance. Tablets were weighed individually and compared with
the average weight [68].
Thickness test:
Ten tablets were selected randomly and thickness was assessed using a Vernier
caliper/screw gauge.
Diameter:
It also dimensionally described & controlled. Tablet diameter can be measured for
six tablets by Dial caliper [69].
Friability test:
Friability is the loss of weight of tablet in the container due to removal of fine particles
from the surface. Friability test is carried out to access the ability of the tablet to
withstand abrasion in packaging, handling and transport [70].
Friability of the tablets was determined using Roche friabilator at 25 rpm/min for
4 min. the device subjects the tablet to the combined effect of abrasion and shock in
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a plastic chamber revolving at 25 rpm and dropping a tablet at I height of 6 inches in
each revolution. Pre weighted sample of tablets was placed in the friabilator and
were subjected to the 100 revolutions. Tablets were dusted using a soft muslin cloth
and reweighed. Twenty tablets were weighed and loss in weight (%) was calculated.
The friability (F) is given by the formula,
%Friability =[(W1-W2)100]/W1
Where,
W1 : weight of tablet before test,
W2 : weight of tablet after test
Disintegration study:
The disintegration test determines whether dosage forms such as tablets, capsules,
suppositories disintegrate with in prescribed time when placed in a liquid medium
under the prescribed experimental conditions.
Disintegration is defined as the state in which no residue of the unit under test
remains on the screen of the apparatus or if a residue remains it consists of
fragments of disintegrated parts of tablet component part such as insoluble coating
of tablets.
Disintegrants are agents added to tablet and some encapsulated
formulations to promote the breakup of the tablet and capsule “slugs” into smaller
fragments in an aqueous environment there by increasing the available surface area
and promoting a more rapid release of the drug substance. They promote moisture
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penetration and dispersion of the tablet matrix. Tablet disintegration has received
considerable attention as an essential step in obtaining fast drug release.
Disintegrants are an essential component to tablet formulations. The ability to
interact strongly with water is essential to disintegrant function. Combinations of
swelling and/or wicking and/or deformation are the mechanisms of disintegrant
action [71].
There are three methods of incorporating disintegrating agents into the tablet:
A. Internal Addition (intragranular)
B. External Addition (extragranular)
C. Partly Internal and External.
Assay :
Magnesium Glycine Complex Equivalent to Elemental Magnesium By Titration
Preparation of Ammonium chloride solution pH 10.0 :
Dissolve 5.4g of ammonium chloride in 20ml of water, add 35ml of 10M
ammonia solution and dilute to 100ml with water.
Preparation of 2M Hydrochloric acid solution :
Dilute 17ml of hydrochloric acid to 100ml with water.
Preparation of 0.05M Disodium Edetate :
Dissolve 18.6g of disodium 50dentate  in 500ml of water and dilute to 1000ml
with water.
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Standardization of 0.05M Disodium EDTA :
Dissolve 0.100g of calcium carbonate in granules in 3ml of hydrochloric acid and
add 100ml of water add 30ml of Ammonium chloride Buffer Ph 10 and add 5mg of
Erichrome black T Titrate with the 0.05M disodium edentate solution until the violet-
pink colour changes to Blue colour.
Each ml of disodium edentate is equivalent to 5.0169 mg of CaCo3.
Blank :
Add 5ml of water then add 5ml of 2M Hydrochloric acid into a 250 ml conical flask
and mix well. Add 150 of water then add 5ml of ammonium chloride solution Ph 10.0
and add 5mg of Erichrome black T. Heat to water bath about 400c for 5 min then
titrate at this temperature with 0.05M Sodium edentate, until the colour changes to
permanent blue.
Sample preparation:
Weigh 20 tablets and transfer to mortar pestle triturate into fine powder. Accurately
weigh and transfer the sample equivalent to 25mg of Magnesium into a 250ml
conical flask add 5ml of water then add 5ml of 2m Hydrochloric acid and sonicate for
15 minutes. After sonication add 150ml of water then add 5ml of ammonium chloride
solution pH 10.0 and add about 5mg of Erichrome black T. Heat to water bath about
400c for 5 min then titrate at this temperature with 0.05M Sodium edentate, until the
colour changes to permanent blue [72].
Note: 1ml of 0.05M Sodium edtate is equivalent to 1.215mg of Mg.
Department of Pharmaceutics AKCP
M
A
T
E
R
IA
L
S
 &
 M
E
T
H
O
D
S
52
Calculation:
Titre value (sample – blank) × Eq.wt factor × Required Molarity/Weight taken in mg ×
Actual Molarity ×Average weight of the tablet in mg
= /mg/tablet
% of lable claim = mg/tablet/lable claim in mg × 100
Vitamin D3 by HPLC (UV/PDA Detector) :
Mobile phase & Diluent: Methanol
Blank :
Pipette out 5ml of Dimethyl sulfoxide into a 100ml volumetric flask and make to
volume with diluent.
Standard Preparation :
Accurately weigh about 20mg of vitamin D3 (100 IU/ mg) into a dried 100 ml amber
colour volumetric flask, add 5ml of Dimethyl sulfoxide and sonicate for 15 minutes at
below 250c, then add 30ml of Methanol sonicate for 10 minutes at bellow 250c and
make up to the volume with diluent. Filter the solution through 0.45µm nylon
membrane filter.
Sample preparation :
Weigh 20 tablets and transfer to mortar pestle, triturate into fine powder. Accurately
weigh and transfer the sample Equivalent to 2000 IU of vitamin D3 into a dried 100
ml amber colour volumetric flask, add 5ml of Dimethyl sulfoxide and sonicate for 15
minutes at below 250c, then add 30ml of Methanol sonicate for 10 minutes at bellow
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250C and make up to the volume with diluent. Filter the solution through 0.45µm
nylon membrane filter.
Chromatographic condition
Column : Intsil C18 (250 *4.6mm) 5µm or equivalent
Flow Rate : 1.5ml/minute
Injection volume : 50µl
Column Oven Temperature : 450c
Sample Temperature :50C
Wavelength : 264 nm
Run time : 15 minutes
Procedure
Separately inject equal volumes (about 50 µl) of the blank, standard preparation and
sample preparation into the chromatograph, record the chromatograms, and
measure the response of major peak.
Evaluation of system suitability
Chromatograph the standard preparation and the peak responses as directed under
the procedure. The test is not valid unless,
a) The tailing factor for vitamin D3 peak in the standard should not be more than
2.0.
b) The number of theoretical plates for vitamin D3 peak should not be less than
2000.
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c) The relative standard deviation for the area of vitamin D3 peak for replicate
injection of standard preparation should not be more than 2.0%.
Calculation :
Vitamin D3
AT×WS×100×P/AS×100×WT×100  ×AW×100  =       IU/TABLET
% lable claim = IU/tablet / LC × 100
Where,
AT : Average area of vitamin D3 peak from sample preparation
AS : Average area of vitamin D3 peak from standard preparation
WS : weight of Vitamin D3 working standard in mg
WT : weight of the sample in mg
P : percentage purity of vitamin D3 working standard as is basis
LC : Label claim in mg
Aw : Average weight of the tablet in mg
Dissolution studies:
As per USP dissolution is not required for oil soluble Vitamins (Vitamin A, D, E, K).
Dissolution Test Requirements for Nutritional Supplements
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Specifications are provided in USP 23, Supplement 9.USP classifications. Table I
lists the dissolution test requirements and references for the six USP classes of
vitamins, minerals, and vitamins with minerals.
Table No 5:4
USP Classifications with respective dissolution test requirements and
references.
Class Dissolution
I. Oil-soluble vitamins Not required
II. Water-soluble vitamins
One index vitamin; folic acid if
present
III. Water-soluble vitamins with
minerals
One index vitamin and one index
element; folic acid if present
IV. Oil- and water-soluble vitamins
One index water-soluble vitamin;
folic acid if present
V. Oil- and water-soluble vitamins
with minerals
One index water-soluble vitamin and
one index element; folic acid if
present
VI. Minerals One index element
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6. FORMULATION DEVELOPMENT
Table No 6:1 Inner tablet:
S.No INGREDIENT CATEGORY
1. Cholecalciferol Pharmaceutical active ingredient
Table No 6:2 Outer tablet:
S.No INGREDIENT CATEGORY
1. Magnesium Glycine
Complex
Best absorbed form of Magnesium
Table No 6:3 Excipients list for IT formulation:
S.NO
Excipients Category
1. Micro Crystalline Cellulose Suspending agent
2. Povidone Adhesive
3. Iso Propyl Alcohol Dissolving oils
4. Crospovidone Disintegrating agent
5. Colloidal silicon di oxide Anti-caking
6. Talc Glidant
7. Magnesium Stearate Anti-adherent
8. Instacoal white Pigments
9. Erythrosine lake Cherry pink
10. Brilliant blue lake Reddish blue powder
11. Methylene chloride Volatile liquid
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Table No 6:4 Excipients for OT formulation:
S.No Excipients Category
1. Micro crystalline cellulose Anti-caking
2. Sodium starch glycolate Disintegrant
3. Povidone Adhesive
4. Iso propyl alcohol Dissolving oils
5. Crospovidone Disintegrant
6. Micro crystalline cellulose Anti-caking
7. Colloidal silicone di oxide Anti-caking
8. Talc Glidant
9. Magnesium stearate Anti-adherent
10. Instacoat white Pigments
11. Erythrosine lake Cherry pink
12. Brilliant blue lake Reddish blue powder
13. Iso propyl alcohol Anti-septic
14. Methelene chloride Volatile liquid
Different batches of  Vitamin D3 tablet (F1to F5)were prepared with varying
concentrations of different formulation ingredients according to Table. The amount
required for formulation is given for following Table.
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Table No 6:5 Formulation for IT formulation:
S.No Name of the
Materials
F – 1
(kg)
F – 2
(kg)
F - 3
(kg)
F – 4
(Kg)
F – 5
(kg)
1. Cholecalciferal 0.15 0.150 0.150 0.150 0.150
2. Mannitol 0.165 0.165 0.165 0.165 0.165
3. Micro crystalline
Cellulose
0.065 0.075 0.025 0.045 0.035
4. Povidone 0.015 0.015 0.015 0.015 0.015
5. Iso Propyl Alcohol 0.15 0.15 0.15 0.15 0.15
6. Crospovidone 0.0075 0.0175 0.0325 0.0125 0.0225
7. Colloidal silicon
di oxide
0.004 0.004 0.004 0.004 0.004
8. Talc 0.004 0.004 0.004 0.004 0.004
9. Magnesium
Stearate
0.003 0.002 0.004 0.004 0.004
10. TOTAL 80.00 80.00 80.00 80.00 80.00
11. Instacoal white 0.0139 0.0139 0.0139 0.0139 0.0139
12. Erythrosine lake 0.0004 0.0004 0.0004 0.0004 0.0004
13. Brilliant blue lake 0.00025 0.00025 0.00025 0.00025 0.00025
14. Iso propyl alcohol 0.095 0.095 0.095 0.095 0.095
15. Methylene chloride 0.178 0.178 0.178 0.178 0.178
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Table No 6:6 Formulation for OT formulation:
S.No Name of the
Materials
F – 1
(kg)
F – 2
(kg)
F - 3
(kg)
F – 4
(Kg)
F – 5
(kg)
1. Magnesium glycine
complex
6.25 6.25 6.25 6.25 6.25
2. Micro crystalline
cellulose
0.4 0.7 0.2 0.4 0.5
3. Sodium starch
glycolate
0.225 0.225 0.225 0.225 0.225
4. Povidone 0.25 0.25 0.25 0.25 0.25
5. Iso propyl alcohol 3.1875 3.1875 3.1875 3.1875 3.1875
6. Crospovidone 0.255 0.305 0.295 0.275 O.265
7. Micro crystalline
cellulose
0.04 0.03 0.07 0.05 0.06
8. Colloidal silicone di
oxide
0.05 0.06 0.02 0.04 0.04
9. Talc 0.03 0.03 0.03 0.03 0.03
10. Magnesium stearate 0.08 0.08 0.08 0.08 0.08
11. TOTAL 1520.00 1520.00 1520.00 1520.00 1520.0
12. Instacoat white 0.2706 0.2706 0.2706 0.2706 0.2706
13. Erythrosine lake 0.012 0.012 0.012 0.012 0.012
14. Brilliant blue lake 0.006 0.006 0.006 0.006 0.006
15. Iso propyl alcohol 1.4375 1.4375 1.4375 1.4375 1.4375
16. Methelene
chloride
2.67 2.67 2.67 2.67 2.67
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Manufacturing process:
Inner part:
Step 1: Sifting:
1. Intra Granular: Sift total dispensed quantity of Vitamin D3, Mannitol and
Microcrystalline Cellulose through 40-mesh (420m) sieve and collect into
separate clean double LDPE poly bags & appropriately labeled.
2. Extra Granular: Sift total dispensed quantity of Crospovidone, Colloidal
Silicon Dioxide and Talc through 40-mesh (420m) sieve and collect into
separate clean double LDPE poly bags & appropriately labeled.
3. Sift total dispensed quantity of Magnesium Stearate through 40-mesh
(420m) sieve and collect into separate clean double LDPE bag and
appropriately labeled.
Step 2 : Binder solution preparation :
Solution: In a suitable stainless steel vessel fitted with stirrer, add Isopropyl Alcohol
and start continuous stirring with required RPM to form a vortex.  Add total
dispensed quantity of PVP slowly into the vortex to get clear solution.
Step 3 : Granulation :
Load total sifted quantity of Intra Granular part of Vitamin D3, Mannitol and
Microcrystalline Cellulose into the Ribbon Mixer and mix for 10 minutes in Clockwise
direction.
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1. Add the binder solution slowly for 2-3 minutes into the above Ribbon mixer
and granulated.
2. If required add additional quantity of Isopropyl Alcohol and mix it for further
3minutes to get the uniform wet mass.
3. Collect the above wet mass in a Trays and fixed into Tray Drier. Start drying
the granules at 35 - 40°C (inlet temperature) to reach the moisture content of
6.0 to 8.0%.
4. Check the moisture content of granules by using moisture balance at 60°C. If
the granules not reach the moisture limit (6.0 - 8.0 %), dry the wet mass until
the granules reach the above moisture limit. Shuffle the granules at every
15minutes.
Table No 6:7 Blending & Lubrication
Blending &
Lubrication
Description
Assay
White to Off white
colored granular powder.
Each 80 mg of Lubricated
Blend Contains:
Vitamin D3   IP : 1200IU
After
Completion of
lubrication
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Pass the above semi dried granules through Vibro sifter using 16 # mesh sieve.
1. Collect the sieved granules in Tray Drier trays and fixed into Tray Drier. Start
drying at 35-40°C (inlet temperature) to the granules reach the moisture
content of 1.0 to 1.5%.
2. Pass the dried granules through Vibro sifter using 20 # mesh and oversized
granules are milled through multi mill using 1.5 mm screen at required speed
at forward direction and again sifted the milled granules through 30 # mesh
3. Collect the sifted dried granules into IPC bin lined with double poly bag.
Step 4 : Blending and Lubrication :
1. Add Crospovidone, Colloidal Silicon Dioxide and Talc(extra granular) into the
Ribbon Mixer containing dried and sized granules and blend for 10 minutes.
2. Add Magnesium stearate (Lubrication part) into the above Ribbon Mixerand
mix for 5 minutes.
Collect samples from different location of HDPE container lined with poly bag and
ensure the content uniformity of the drug through process validation protocol. Until
required for tableting, the bulk lubricated Blend is stored in a secure holding area
NMT 25C and RH should be not more than 60%.
Step 5 : Compression : (Inner Tablet)
1. Set the compression machine with 5.5 mm Plain, Circular shape standard
concave punches and dies (Refer –annexure MFR: FD: 012: A1/00).
2. Charge the lubricated blend into hopper to allow the compression machine
and start the machine.
3. Check the product for all quality parameters as per In-process Specifications.
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4. Set the compression machine and continue the compression after setting all
the quality parameters.
5. Pass the compressed tablets through de-duster and collect the tablets in
clean bulk container lined with double polythene bag.
6. Record all the details in the BMR – In-process Check Record.
7. The core tablets are then transferred to quarantine bulk hold area till reported
for Coating.
Step 6 : Preparation of coating solution and coating process:
(Manual Coating Pan)
1. Disperse separately dispensed quantity of Instacoat White, Erythrosine Lake
& Brilliant Blue Lakein and Isopropyl Alcohol in a suitable SS vessel. Stir well
at 500-1200 RPM by means of Remi stirrer or 10-40 Hertz in Solution
Preparation Vessel for about 5 minutes. Then add Methylene chloride and Stir
well for about 25 minutes at required RPM. Then passed the above solution
through colloid mill at required RPM and again stir the solution for about 20
minutes at 500-1200 RPM. Filter the solution through muslin cloth. Record the
stirring time & Mixing speed. Carry out the film coating process.
2. Transfer the totalquantity of the core tablet into the coating pan and pre heat
the tablet bed by using warm air at 35-50C. Transfer the coating solution to
solution tank, attach the spray gun and connected with peristaltic pump.
Continue stirring of coating solution at slow speed throughout the process.
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Table No 6:8 Processing Parameters
S.NO PROCESS PARAMETERS LIMIT
1 Pan Manual Coating Pan-36”
2 Pan speed 2–8 RPM
3 Quantity charged 3,00,000tabs(24.00 kg)
4 Inlet temperature 35C -50C
5 Bed Temperature 35 – 50°C
6 Atomization pressure 1.4 to 4.2 kg/cm2
7 RPM of peristaltic pump 12 - 50 RPM
8 Spray rate 40-100 g/min  (per gun)
3. Switch on the mains and start the pan. Record RPM of pan, inlet temperature,
spray gun air pressure, RPM of peristaltic pump, & spray rate.
4. Spray the coating solution over the rolling tablets at a constant rate, while
running the Coating pan machine continuously, in order to cover the surfaces
of tablets uniformly.
5. Based on observed average weight of core tablets, weight gain required for
2.8 to 3.2 % (Target 3.0%).Record the film-coating time in BMR.
6. If weight gain achieved between 2.80% to 3.20% stop pump and spray unit.
Keeps the pan rotating with heating at 50°C for 15 minutes.
7. Then Switch off the heater at pan speed 1 RPM for 30 mins.  After completion
of coating, remaining coating solution to be destroyed.
8. Unload the film-coated tablets into suitable HDPE containers lined with double
poly bags. Labelled the HDPE container properly.
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Outer part:
Step 1: Sifting
1. Intra Granular: Sift dispensed quantity of Magnesium Glycine Complex,
Microcrystalline Cellulose and sodium Starch Glycolate through 40-mesh
(420m) sieve and collect into separate clean double LDPE poly bags &
appropriately labeled.
2. Extra Granular: Sift dispensed quantity of Microcrystalline Cellulose,
Crospovidone, Colloidal Silicon Dioxide and Talc through 40-mesh (420 m)
sieve and collect into separate clean double LDPE poly bags & appropriately
labeled.
3. Sift dispensed quantity of Magnesium Stearate through 40-mesh (420 m)
sieve and collect into separate clean double LDPE bag and appropriately
labeled.
Step 2: Binder solution preparation:
1. Solution: In a suitable stainless steel vessel fitted with stirrer, add Isopropyl
Alcohol and start continuous stirring with required RPM to form a vortex.  Add
total dispensed quantity of PVP slowly into the vortex to get clear solution.
Step 3 : Granulation
1. Load total of Intra Granular part of Magnesium Glycine Complex,
Microcrystalline Cellulose and sodium Starch Glycolate into the Rapid mixer
granulator and mix for 15 minutes with slow impeller.
2. Add the binder solution slowly for 3-6 minutes with slow impeller,
No Chopper into the above Rapid mixer granulator.
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3. If required add additional quantity of Isopropyl Alcohol and mix it for further
2-3 minutes.
4. Collect the above wet mass in a Fluid Bed Drier bowl fix into Fluid Bed Drier.
Start the air drying to vanish the Isopropyl Alcohol.
5. Then start the steam supply and dry the granules at 50-60°C (inlet
temperature) to reduce the Moisture content to 6.00 to 8.00%. Moisture
content checked by using moisture analyser at 105°C temperature
6. Pass the above dried granules through Vibro sifter using 16# mesh sieve.
Oversized granules are milled through multi mill using 2.0 mm screen at
required speed at forward direction, Again sifted the milled granules through
20 # mesh.
7. Collect the sieved and milled granules in a Fluid Bed Drier bowl fix into Fluid
Bed Drier. Start the steam supply and dry the granules at 50-60°C (inlet
temperature) to get granules 1.50 to 2.50 %. Moisture content checked by
using moisture analyser at 105°C temperature
8. Collect the sifted dried granules into IPC bin with silica gel desiccant between
the two black poly bags.
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Step 4 : Blending and lubrication :
Transfer the dried granules & sifted extra granular and lubrication materials into
blending area.
1. Transfer the granules into the Octagonal Blender. Add Microcrystalline
Cellulose, Crospovidone, Colloidal Silicon Dioxide and Talc (extra granular)
into the Octagonal Blender. Its containing dried and sized granules and blend
for 10 minutesat 10 RPM.
2. Add Magnesium stearate (Lubrication part) into the above Octagonal Blender
then mix for 5 minutes at 10 RPM.
Collect samples from different location of HDPE container lined with poly bag and
ensure the content uniformity of the drug through process validation protocol.Until
required for tableting, the bulk lubricated Blend is stored in a secure holding area
NMT 25C and RH should be not more than 60%.
Table No 6:9 Specifications Blending & Lubrication
Stage Checks Specifications Frequency/
Method
Blending &
Lubrication
Description
Assay
White to Off white colored
granular powder.
Each 1520 mg of
Lubricated Blend Contains:
Magnesium Glycine
Complex Eq. to Elemental
Magnesium: 250 mg
After Completion of
lubrication
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Step 5 : Compression: (Tablet in Tablet)
1. Set the compression machine with 22.0 x 10.50 mm Plain, Caplet shape
standard concave punches and dies (Refer –annexure MFR: FD: 012: A1/00).
1. Charge the lubricated blend into hopper to allow the blend into punch cavity.
Then charge the inner coated tablet into the hopper which is available
separately in the machine and allow the inner tablet blend filled cavity and
proceed the compression.
2. Check the product for all quality parameters as per In-process Specifications.
3. Set the compression machine and continue the compression after setting all
the quality parameters.
4. Pass the compressed tablets through de-duster and collect the tablets in clean
bulk container lined with double polythene bag.
5. Record all the details in the BMR – In-process Check Record.
6. The tablets in tablet are then transferred to quarantine bulk hold area till
reported for Coating.
7. Maximum Hold time 15 days of core tablet to be evaluated through Hold time
study protocol.
Step 6 : P reparation of Coating solution & coating process :
1. Disperse separately dispensed quantity of Instacoat White, Erythrosine
Lake&Brilliant Blue Lakein and  Isopropyl Alcohol in a suitable SS vessel. Stir
well at 500-1200 RPM by means of Remi stirrer or 10-40 Hertz in Solution
Preparation Vessel for about 5 minutes. Then add Methylene chloride and Stir
well for about 25 minutes at required RPM. Then passed the above solution
through colloid mill at required RPM and again stir the solution for about 20
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minutes at 500-1200 RPM. Filter the solution through muslin cloth. Record the
stirring time & Mixing speed. Carry out the film coating process.
2. Transfer the quantity of tablet in tablet into the coating pan and pre heat the
tablet bed by using warm air at 35-50C. Transfer the coating solution to
solution tank, attach the spray gun and connected with peristaltic pump.
Continue stirring of coating solution at slow speed throughout the process.
3. Switch on the mains and start the pan. Record RPM of pan, inlet temperature,
spray gun air pressure, RPM of peristaltic pump, & spray rate.
4. Spray the coating solution over the rolling tablets at a constant rate, while
running the Coating pan machine continuously, in order to cover the surfaces
of tablets uniformly.
5. Based on observed average weight of core tablets, weight gain required for
2.8 to 3.2 % (Target 3.0%). Record the film-coating time in BMR.
6. If weight gain achieved between 2.80% to 3.20% stop pump and spray unit.
Keeps the pan rotating with heating at 50°C for 15 minutes.
7. Then Switch off the heater at pan speed 1 RPM for 30 mins. After completion
of coating, remaining coating solution to be destroyed.
Table No 6:10 Processing Parameters
S.No Process Parameters Limit
1 Pan Auto Coater-48”
2 Pan speed 2–8 RPM
3 Quantity charged 75,00,000tabs (120.18 kg)
4 Inlet temperature 35C -50C
5 Bed Temperature 35 – 50°C
6 Atomization pressure 1.4 to 4.2 kg/cm2
7 RPM of peristaltic pump 12 - 50 RPM
8 Spray rate 40-100 g/min  (per gun)
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7. RESULT AND DISCUSSION
PREFORMULATION STUDIES:
The overall objective of preformulation studies is to generate useful information to the
formulator in developing stable and bioavailable dosage forms that can be mass
produced.
Table: 7.1 Saturation solubility:
S No. Medium Solubility
1 Methanol Soluble
2 Water Insoluble
3 7.4 phosphate buffer Soluble
Calibration curve
Table : 7.2 Calibration curve
S.NO Calibration (µg ) Absorbance
1 0 0
2 5 0.104
3 10 0.271
4 15 0.459
5 25 0.648
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Fig 7:1 Calibration curve
Table no 7:1 Preformulation Studies of IT Powder
Formulation
Angle of
Repose
Mean ± SEM
Bulk
density
Mean ±
SEM
Tapped
density
Mean ± SEM
Carr’s
index
Mean ±
SEM
Hausners
ratio
Mean ±
SEM
F1 21.87 ± 0.99 0.59± 0.18 0.66 ±  0.87 14.99 ± 0.09 1.95 ± 0.34
F2 20.14 ± 0.48 0.51 ± 0.65 0.62 ±  0.23 13.78 ± 0.15 1.80 ± 0.87
F3 22.65 ± 0.11 0.50 ± 0.09 0.66 ±  0.62 13.26 ± 0.65 1.98 ± 0.65
F4 21.09 ± 0.99 0.51 ± 0.98 0.64 ±  0.45 14.76 ± 0.33 1.54 ± 0.23
F5 23.65 ± 0.54 0.53 ± 0.87 0.61 ±  0.54 14.43 ± 0.51 1.33 ± 0.98
All values are expressed as mean ± SEM for six determinations
0, 0
5, 0.104
10, 0.271
15, 0.459
20, 0.648
y = 0.033x - 0.0338
R² = 0.9891
-0.1
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0 5 10 15 20 25
A
bs
o
rb
a
n
ce
Concenration (μg/ml)
Calibration of model drug in 7.4 pH buffer
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Table No 7:2 Physical Parameters of IT formulation: (before coating)
Formulation Weight
Variation(mg)
Hardness
test(kg/cm2)
Thickness
test(mm)
Diameter
(mm)
Friability
%
F1 81.23 ± 0.99 3.9 ± 0.14 2.56 ± 0.23 5.40± 0.66 0.4%
F2 80.60 ± 0.98 4.1 ± 0.54 2.43 ± 0.87 5.36± 0.32 0.5%
F3 81.02 ±  0.54 4.0 ± 0.33 2.54± 0.99 5.34± 0.87 0.4%
F4 81.99 ±  0.33 4.3 ± 0.21 2.44± 0.11 5.45± 0.54 0.4%
F5 80.80 ±  0.98 4.7 ± 0.87 2.51± 0.66 5.48± 0.33 0.5%
All values are expressed as mean ± SEM for six determinations
Table No 7:3 Physical Parameters of  IT formulation: (after coating )
Formulation
Weight
Variation(mg)
Thickness
test (mm)
Diameter
(mm)
F1 82.43 ±  0.18 2.62 ±  0.87 5.48 ± 0.78
F2 82.42 ±  0.65 2.54 ±  0.11 5.44 ± 0.11
F3 82.41 ±  0.87 2.61 ±  0.24 5.43 ± 0.54
F4 82.40 ±  0.77 2.56 ±  0.28 5.51 ± 0.87
F5 82.40 ±  0.82 2.59 ±  0.99 5.53 ± 0.65
All values are expressed as mean ± SEM for six determinations
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Table no 7:4 Drug content
S.NO Formulation Drug content uniformity (%)
1 F1 91.20%
2 F2 91.67%
3 F3 93.80%
4 F4 97.40%
5 F5 96.23%
Table no 7:5 Preformulation Studies of OT Powder
Formulation Angle of
Repose
Mean ± SEM
Bulk
density
Mean± SEM
Tapped
density
Mean ± SEM
Carr’s index
Mean ± SEM
Hausners
ratio
F1 22.91 ± 0.587 0.58 ± 0.06 0.67 ±  0.09 13.32 ± 0.10 1.15 ± 0.11
F2 23.76 ± 0.453 0.58 ± 0.05 0.64 ±  0.11 13.99 ± 0.95 1.10 ± 0.11
F3 21.01 ± 0.867 0.61 ± 0.11 0.67 ±  0.12 14.32 ± 0.47 1.07 ± 0.17
F4 23.81 ± 0.767 0.59 ± 0.07 0.65 ±  0.09 15.56 ± 0.97 1.09 ± 0.15
F5 23.08 ± 0.437 0.58 ± 0.09 0.66 ±  0.04 14.87 ± 0.48 1.11 ± 0.05
All values are expressed as mean ± SEM for six determinations
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Table No 7:6 Physical Parameters of  OT formulation :
Formulation
Weight
variation
Hardness
test
(kg/cm2)
Thickness
(mm)
Diameter
(mm)
Friability
%
F1 1621 ± 0.12 4.2 ± 0.12 6.81 ± 0.04 10.52 ± 0.14 0.5%
F2 1625 ± 0.23 4.1 ± 0.14 6.81 ± 0.05 10.49 ± 0.24 0.4%
F3 1619 ± 0.09 4.1 ± 0.54 6.78 ± 0.02 10.50 ± 0.05 0.5%
F4 1624 ± 0.10 4.6 ± 0.61 6.80 ± 0.01 10.50 ± 0.62 0.4%
F5 1622 ± 0.41 4.7 ± 0.71 6.80 ± 0.03 10.51 ± 0.71 0.5%
All values are expressed as mean ± SEM for six determinations
Table No 7:7 Physical Parameters of OT formulation: (after coating)
Formulation Weight variation Thickness test Diameter
F1 1634 ± 0.32 4.1 ± 0.04 10.67 ±  0.22
F2 1636 ± 0.54 4.5 ± 0.05 10.58 ±  0.53
F3 1632 ± 0.34 4.6 ± 0.14 10.61 ±  0.12
F4 1633 ± 0.87 4.9 ± 0.62 10.57 ±  0.75
F5 1635 ± 0.98 4.9 ± 0.71 10.59 ±  0.53
All values are expressed as mean ± SEM for six determinations
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Table No 7:8 Disintegration Time (min)
S.NO Formulation Disintegration time (min)
1 F1 7.43 ±  0.53
2 F2 8.87 ±  0.22
3 F3 7.53 ± 0.05
4 F4 6.32 ± 0.32
5 F5 7.76 ± 0.71
Table No. 7:9 Dissolution profile of formulation of Vitamin d3 tablet
Time Dissolution
Test F1
Dissolution
Test F2
Dissolution
Test F3
Dissolution
Test F4
Dissolution
Test F5
0 0 0 0 0 0
10 28.25 23.95 28.25 30.21 31.41
20 65.33 47.93 45.33 58.99 55.33
30 84.24 71.65 76.88 78.96 79.25
45 87.23 84.89 85.25 92.47 91.45
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Fig 7:2 Dissolution profile of formulation of Vitamin D3 tablet
Assay: Method:E:\PROJECTS\AD_INS_006\2016\October\Method\ Cholicalciferol
tablet
Assay & UOC.met Sequence: \PROJECTS\AD_INS_006\2016\October\Sequence\
Cholicalciferol tablet  Assay & UOC.seq Acquired:18-10-2016 13:06:28 (GMT
+05:30)
Printed Time:18-10-2016 15:37:32
(GMT +05:30) Sample ID:Standard
Assay
Injection
volume:20µl
Vial no:42
Cloumn ID:  AD/LCCN/124
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s
Wet granulation process was used to prepare the magnesium Carbonate and
vitamin D3 tablets by using different types of excipients used. Tablet properties were
evaluated by performing various tests. The result of weight variation test was +
0.54% and -1.43%. The weight variation test is alternative to content uniformity test
that assure the therapeutic utility. Weight variation test is an also an indicator of
variations in the drug content. Standards and specifications have given in
Pharmacopoeias that provide permissible limits for weight variation. Result of width
and thickness was 6.2 mm respectively. The result of hardness was 10 kg
(permissible limit is not less than 4.0 kg) which meet the permissible limit. Friability
test indicates the mechanical strength. According to Pharmacopoeia friability for
compressed tablet is not more than 1.0%. The result of magnesium and Vitamin D3
tablet was 0.14%. After physical tests the tablets were subjected to chemical tests.
Assay, disintegration and tests were carried out for evaluation of chemical
properties. Availability of a drug for dissolution and absorption is determined by
evaluation of disintegration. The result showed that tablets took 5 minutes to
10
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disintegrate (permissible limit is not more than 15 minutes). Content of Cholicalciferol
was determined by HPLC method and the result was 243.4 IU (permissible limit is
180.0 IU -330.0 IU). The Calcium content was assayed by Titrimetric Method and
result was 432.07 mg (permissible limit is 450.0 mg -550.0 mg).From the above data
it was found that Vitamin D3 formulation (F4), the %drug release was found to be
92.47% at 45 mins time.
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8. STABILITY STUDIES
Quality guidelines known as ICH guidelines have established a series of
guidelines acceptable to multiple countries for the drug approval process. (ICH
Guidelines) It is a normal practice to study the stability of pharmaceutical
preparations at accelerated conditions of temperature and humidity, the
experimental findings which can be transformed into reliable shelf life or expiry
date by adopting certain assumptions or criterions (Cannorset al.1979). In
comparison to conventional preparations Pharmaceutical product represents
number of unique problems when quality and stability are considered. To
ensure proper reproducibility, proper control is essential an important part of
quality control is to ensure the chemical stability of final product during storage
product. Present study is an attempt to study accelerated stability of Vitamin
D3 tablet in tablets, these have been prepared using time tested
pharmaceutical ingredient in optimum concentration which includes Vitamin D3
tablet in tablet formulation.
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METHODS
The present work on “Accelerated Stability study of Suppliment” was
undertaken to standardize and study the stability profile of Vitamin D3 tablet in
tablet formulation. The study was done at accelerated temperature and
humidity conditions, i.e. accelerated stability study taking ICH guidelines as
reference. The ten tablets were randomly collected. Enough blisters in duplex
were kept in humidity chamber at 40
0
±2
0
c and 70 ± 5% RH humidity.
Required blisters were withdrawn after one, two, three and six month in
triplicate for analysis. The main ingredient of Vitamin D3 tablet in table
formulation initial sample 1, 2, 3 and 6 month of storage at accelerated
conditions of temperature and humidity. For evaluation different parameters
were taken that were organoleptic evaluation, identification tests, Average
weight test, disintegration test, dissolution test. Samples were tested at the
time of their release of batch and after 1st, 2nd, 3rd and 6th month of storage.
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Table No 8:1 Results of different parameters used for Accelerated Stability study data of selected Vitamin D3 tablet in tablet
formulations subjected to study as per ICH guidelines (3month at 40°C ± 2°C and 75%RH ± 5% RH). At predetermined time intervals
of 1, 2, 3 and 6 month.
Days Formulation Colour
and
Odour
pH Weight
variation test
Friability
test
Hardness test Thickne
ss test
Disintegrati
on test (sec)
Assay Solubility Dissolution
test
0 Day
F -1 No
change
6.7 1641 0.96% No change 4.4% 4.00min 95.82% No change Good
F -2 No
change
6.4 1643 1.01% No change 4.5% 3.45min 96.21% No change Good
F -3 No
change
6.8 1642 1.5% No change 4.5% 4.54min 97.11% No change Good
F -4 No
change
6.6 1644 1.5% No change 4.3% 4.12min 96.01% No change Good
F -5 No
change
6.3 1644 0.9% No change 4.2% 4.34min 95.22% No change Good
60
Days
F -1 No
change
6.6 1642 1.01% No change 4.4% 4.00min 94.82% No change Good
F -2 No
change
6.0 1645 0.9% No change 4.6% 3.45min 96.37% No change Good
F -3 No
change
6.3 1643 1.5% No change 4.2% 4.54min 96.23% No change Good
F -4 No
change
5.9 1644 0.9% No change 4.1% 4.12min 94.19% No change Good
F -5 No 6.7 1641 1.01% No change 4.2% 4.34min 96.23% No change Good
Department of Pharmaceutics AKCP
S
T
A
B
IL
IT
IY
S
T
U
D
IE
S
82
No visible physical and chemical changes observed in any one the product during storage period. Vitamin D3 tablet in tablet
formulation conducted Color and Odour, pH, Wight variation test, Friability test, Hardness test, Thickness test, Disintegration test
(sec), Assay, Solubility, Dissolution test all the product should be stable in the Accelerated storage period of 6 month.
change
90
Days
F -1 No
change
6.5 1645 1.5% No change 4.4% 4.00min 93.21% No change Good
F -2 No
change
5.9 1644 0.9% No change 4.2% 4.15min 94.7% No change Good
F -3 No
change
6.2 1645 1.01% No change 4.1% 4.24min 96.58% No change Good
F -4 No
change
5.9 1643 1.5% No change 4.3% 5.52min 95.19% No change Good
F -5 No
change
6.4 1644 0.9% No change 4.4% 5.34min 94.34% No change Good
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9. SUMMARY AND CONCLUTION
The present research work is design and evaluate  tablet in tablet of  Magnesium and
Vitamin D3 tablets (250 mg/1200 IU). Vitamin D is important for bone structure. If there
is too little Vitamin D available not enough calcium reaches the blood through the
intestinal walls. Magnesium & vitamin D essential for bone synthesis otherwise intensify
to Osteoporosis. Mg is also credited with stabilizing functions in bone building. If there is
no stabilizing function of Mg during bone synthesis, this also decrease bone density.
The term Osteoporosis already indicates a lack of calcium in the bones. Mg & vitamin D
rich diet can help to bring calcium back to where it belongs. All the formulations were
evaluated for physical characteristics, disintegration, in vitro disintegration study and
stability. Following conclusions have been made from the present study.
Preformulation studies:
The pre-formulation study carried out that angle of repose, bulk density, tapped density,
compressibility, Hausner ratio. The results were clearly shown. Manufacturing process
is lengthy but in the formulated product shows greater stability with adding less
overages.
Evaluation of Designed Formulations:
Post formulation studies
Physical characterization of all the lubricated blends were carried out and found to have
good flow properties. The physical characteristics of all the blended formulations were
satisfactory.
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The tablets prepared with the plain polymer mixture combination were found to have
desired limits of hardness and thickness and complies to weight variation and within the
official limits of friability. The drug release for formulation F4 was found to be 91.34% at
the end of 45 mins. The prepared tablets were evaluated for Weight variation,
Hardness, Friability, Disintegration time, Drug content and The prepared tablets
evaluated for Assay, weight variation, thickness and Disintegration time were found
to be within the official limits. The in vitro disintegration studies were performed for all
the IT and OT formulations. The in vitro dissolution tests. The results were clearly
shown. Accelerated Stability studies were also done for optimized formulation F4, F5 and
the results were found satisfactory. This research work proven formulation tablet in
tablet F4 of shows good stability compared with other 4 formulation.
Conclusion:
The results Vitamin D3 tablet in tablets of evaluation of different batches were done.
The HPLC assy study shows that there was drug content final tablet. The weight
variation limited  tablets was found maximum up to ± 1.2 % RSD. Hardness was found
to be within 3.0 to 4.0 kg/cm2 which limit friability within 0.7% only. The evaluation
results of F4 batches were found to be satisfactory within limit and the disintegration
time (4min). the same ratio the formulation F4 gave 92.47% drug release at 45 mins
time point. The drug Contents was found to be within limits nd all tablets were passing
the dispersion test. Vitamin D3 tablet in tablets of optimized all batch were of
satisfactory stability during 3 months of accelerated stability studies.
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